Carmot Therapeutics, Drug Discovery and Development
About Us
Leadership
Board of Directors & Advisors
Investors & Partners
Contact Us
Our Approach
Chemotype Evolution
Incretin Receptor Signaling Bias
Energy Homeostasis
Our Pipeline
News
Careers
About Us
Leadership
Board of Directors & Advisors
Investors & Partners
Contact Us
Our Approach
Chemotype Evolution
Incretin Receptor Signaling Bias
Energy Homeostasis
Our Pipeline
News
Careers
News
Press Releases
June 06, 2023
Carmot Therapeutics Appoints Michael Gray as Chief Financial Officer and Chief Operating Officer
May 25, 2023
Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes
May 23, 2023
Carmot Therapeutics to Present Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions
January 05, 2023
Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease
September 21, 2022
Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO
July 26, 2022
Carmot Therapeutics closes $160 million Series D financing to advance clinical pipeline of novel incretin receptor modulators
March 01, 2022
Carmot announces Tim Garnett M.D., previously Chief Medical Officer Eli Lilly, joins Carmot’s Board of Directors.
June 29, 2021
Carmot to receive royalty payments upon sales of Amgen’s FDA approved first-in-class
KRAS
G12C Inhibitor, LUMAKRAS™ (sotorasib); Further demonstrates the value of Carmot’s therapeutic platform
June 24, 2021
Carmot Therapeutics Initiates the Clinical Program for CT-388, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Patients with Type 2 Diabetes and Showcases its Technology at the Upcoming American Diabetes Association Scientific Session
May 04, 2021
Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 Diabetes
More Press Releases